Cargando…
Cardiovascular drugs and COVID‐19 clinical outcomes: a systematic review and meta‐analysis of randomized controlled trials
Aims: To update our previously reported systematic review and meta‐analysis of observational studies on cardiovascular drug exposure and COVID‐19 clinical outcomes by focusing on newly published randomized controlled trials (RCTs). Methods: More than 500 databases were searched between 1 November 20...
Autores principales: | Asiimwe, Innocent G., Pushpakom, Sudeep P., Turner, Richard M., Kolamunnage‐Dona, Ruwanthi, Jorgensen, Andrea L., Pirmohamed, Munir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9111446/ https://www.ncbi.nlm.nih.gov/pubmed/35322889 http://dx.doi.org/10.1111/bcp.15331 |
Ejemplares similares
-
Cardiovascular drugs and COVID‐19 clinical outcomes: A living systematic review and meta‐analysis
por: Asiimwe, Innocent G., et al.
Publicado: (2021) -
Warfarin dosing algorithms: A systematic review
por: Asiimwe, Innocent G., et al.
Publicado: (2020) -
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral Therapy
por: Pushpakom, Sudeep, et al.
Publicado: (2020) -
Drug–Drug–Gene Interactions in Cardiovascular Medicine
por: Asiimwe, Innocent G, et al.
Publicado: (2022) -
Telmisartan and Insulin Resistance in HIV (TAILoR): protocol for a dose-ranging phase II randomised open-labelled trial of telmisartan as a strategy for the reduction of insulin resistance in HIV-positive individuals on combination antiretroviral therapy
por: Pushpakom, Sudeep P, et al.
Publicado: (2015)